Author

Allitia DiBernardo

Observed names: A DiBernardo, A. DiBernardo, A. Dibernardo, Allitia B. DiBernardo, Allitia B. Dibernardo, Allitia Dibernardo, DiBernardo, Allitia

Observed institutions: Biogen (United States), Beth Israel Deaconess Medical Center, Feinstein Institute for Medical Research, Johnson & Johnson (United States), Harvard University, Massachusetts General Hospital, Janssen (France), Novartis (United States), Burke Medical Research Institute, Janssen (United States), Janssen Scientific Affairs (United States), Janssen Research & Development (United States), Covance (United States), University of Duisburg-Essen, Massachusetts Institute of Technology, University of Glasgow

OpenAlex ID: A5003330833

Toll-Like Receptor 3 Is a Potent Negative Regulator of Axonal Growth in Mammals

2007 · Jill S. Cameron, Lena Alexopoulou, et al. · Journal of Neuroscience · 233

PDF

Robotic Measurement of Arm Movements After Stroke Establishes Biomarkers of Motor Recovery

2013 · Hermano I. Krebs, Michael Krams, et al. · Stroke · 153

Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data

2012 · for the Alzheimer’s Disease Neuroimaging Initiative, Jieping Ye, et al. · BMC Neurology · 143

PDF

WAVE1 Is Required for Oligodendrocyte Morphogenesis and Normal CNS Myelination

2006 · Hyun-Ju Kim, Allitia B. DiBernardo, et al. · Journal of Neuroscience · 100

PDF

The ADAS‐Cog revisited: Novel composite scales based on ADAS‐Cog to improve efficiency in MCI and early AD trials

2012 · Nandini Raghavan, Mahesh N. Samtani, et al. · Alzheimer s & Dementia · 96

Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden

2018 · Johan Reutfors, Therese M-L. Andersson, et al. · Journal of Affective Disorders · 94

All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population

2019 · Gang Li, Daniel Fife, et al. · Annals of General Psychiatry · 83

PDF

An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative

2011 · Mahesh N. Samtani, Michael Farnum, et al. · The Journal of Clinical Pharmacology · 80

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis

2015 · Timothy Vollmer, James Signorovitch, et al. · Journal of the Neurological Sciences · 79

Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review

2015 · Timothy Vollmer, Lynn Huynh, et al. · Neurological Sciences · 75

Quantifying the Pathophysiological Timeline of Alzheimer's Disease

2011 · Eric Yang, Michael Farnum, et al. · Journal of Alzheimer s Disease · 68

Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study

2018 · Allitia DiBernardo, Xiwu Lin, et al. · BMC Psychiatry · 66

PDF

Risk Factors for Suicide and Suicide Attempts Among Patients With Treatment-Resistant Depression: Nested Case-Control Study

2019 · Johan Reutfors, Therese M.-L. Andersson, et al. · Archives of Suicide Research · 60

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

2012 · Mahesh N. Samtani, Nandini Raghavan, et al. · British Journal of Clinical Pharmacology · 52

PDF

Treatment‐resistant depression as risk factor for substance use disorders—a nation‐wide register‐based cohort study

2019 · Philip Brenner, Lena Brandt, et al. · Addiction · 42

PDF

Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study

2019 · Philip Brenner, Lena Brandt, et al. · Addiction · 41

PDF

A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis

2010 · Nazem Atassi, Eva-Maria Ratai, et al. · Amyotrophic Lateral Sclerosis · 37

Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform

2020 · Stephane Borentain, Abigail I. Nash, et al. · BMC Psychiatry · 36

PDF

Translating preclinical insights into effective human trials in ALS

2006 · Allitia B. DiBernardo, Merit E. Cudkowicz · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 34

PDF

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine

2022 · Stephane Borentain, Jagadish Gogate, et al. · International Journal of Methods in Psychiatric Research · 30

PDF

A register-based approach to identifying treatment-resistant depression—Comparison with clinical definitions

2020 · David Hägg, Philip Brenner, et al. · PLoS ONE · 30

PDF

A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients

2020 · Gang Li, Ling Zhang, et al. · PLoS ONE · 27

PDF

2012: A watershed year for Alzheimer's disease research

2013 · M. Grundman, A. Dibernardo, et al. · The journal of nutrition health & aging · 27

Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed

2020 · Leslie Citrome, Allitia DiBernardo, et al. · Journal of Affective Disorders · 26

Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis

2008 · Muddasir Qureshi, Amy Shui, et al. · Amyotrophic Lateral Sclerosis · 25

Works count: 70

Citation count: 1,876

H-index: 25

I10-index: 31